A CA 19-9, CA 72-4 és a CEA tumorantigének összehasonlító vizsgálata a pancreascarcinoma és az egyéb emésztöszervi malignus betegségek diagnózisában.

Translated title of the contribution: Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The diagnostic value of CA 19-9, CA 72-4 and CEA was evaluated in 291 patients (including 39 with pancreatic cancer, 32 with gastric cancer, 36 with colorectal cancer and 40 with chronic pancreatitis). These markers were determined in the serum by chemiluminescence immunoassay (CA 72-4) or microparticle enzyme immunoassay (CA 19-9 and CEA) methods. In serodiagnostic evaluations relating to pancreatic cancer, CA 19-9 proved superior to CA 72-4 and CEA (sensitivity: 79.5 vs. 56.5 and 62.5%; specificity: 84.1 vs. 77.9 and 77.2%; diagnostic accuracy: 85.9 vs. 75.8 and 75.7%, respectively). For gastric carcinoma, CA 72-4 appeared the most sensitive: 53.1% of all patients were identified with a specificity of 78.9% and a diagnostic accuracy of 75.4%. In the diagnosis; of colorectal cancer, CEA exhibited the highest sensitivity (63.9%) and diagnostic accuracy (76.2%). Elevated CA 19-9 levels were obtained in only 7.7% of patients with chronic pancreatitis. Tumor marker determination is useful in the diagnosis of gastrointestinal malignancies: the marker of choice in pancreatic cancer is CA 19-9, in gastric cancer it is CA 72-4 and in colorectal cancer it is CEA. CA 19-9 is effective in discriminating between pancreatic cancer and chronic pancreatitis.

Original languageHungarian
Pages (from-to)2981-2985
Number of pages5
JournalOrvosi Hetilap
Volume138
Issue number47
Publication statusPublished - Nov 23 1997

Fingerprint

Gastrointestinal Diseases
Neoplasm Antigens
Pancreatic Neoplasms
Chronic Pancreatitis
Colorectal Neoplasms
Stomach Neoplasms
Tumor Biomarkers
Luminescence
Immunoenzyme Techniques
Immunoassay
Stomach
Carcinoma
Serum
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2971c02a4d344364abfff43bd12aed51,
title = "A CA 19-9, CA 72-4 {\'e}s a CEA tumorantig{\'e}nek {\"o}sszehasonl{\'i}t{\'o} vizsg{\'a}lata a pancreascarcinoma {\'e}s az egy{\'e}b em{\'e}szt{\"o}szervi malignus betegs{\'e}gek diagn{\'o}zis{\'a}ban.",
abstract = "The diagnostic value of CA 19-9, CA 72-4 and CEA was evaluated in 291 patients (including 39 with pancreatic cancer, 32 with gastric cancer, 36 with colorectal cancer and 40 with chronic pancreatitis). These markers were determined in the serum by chemiluminescence immunoassay (CA 72-4) or microparticle enzyme immunoassay (CA 19-9 and CEA) methods. In serodiagnostic evaluations relating to pancreatic cancer, CA 19-9 proved superior to CA 72-4 and CEA (sensitivity: 79.5 vs. 56.5 and 62.5{\%}; specificity: 84.1 vs. 77.9 and 77.2{\%}; diagnostic accuracy: 85.9 vs. 75.8 and 75.7{\%}, respectively). For gastric carcinoma, CA 72-4 appeared the most sensitive: 53.1{\%} of all patients were identified with a specificity of 78.9{\%} and a diagnostic accuracy of 75.4{\%}. In the diagnosis; of colorectal cancer, CEA exhibited the highest sensitivity (63.9{\%}) and diagnostic accuracy (76.2{\%}). Elevated CA 19-9 levels were obtained in only 7.7{\%} of patients with chronic pancreatitis. Tumor marker determination is useful in the diagnosis of gastrointestinal malignancies: the marker of choice in pancreatic cancer is CA 19-9, in gastric cancer it is CA 72-4 and in colorectal cancer it is CEA. CA 19-9 is effective in discriminating between pancreatic cancer and chronic pancreatitis.",
author = "L. Czak{\'o} and T. Tak{\'a}cs and E. Babarczy and L. Dux and J. Lonovics",
year = "1997",
month = "11",
day = "23",
language = "Hungarian",
volume = "138",
pages = "2981--2985",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - A CA 19-9, CA 72-4 és a CEA tumorantigének összehasonlító vizsgálata a pancreascarcinoma és az egyéb emésztöszervi malignus betegségek diagnózisában.

AU - Czakó, L.

AU - Takács, T.

AU - Babarczy, E.

AU - Dux, L.

AU - Lonovics, J.

PY - 1997/11/23

Y1 - 1997/11/23

N2 - The diagnostic value of CA 19-9, CA 72-4 and CEA was evaluated in 291 patients (including 39 with pancreatic cancer, 32 with gastric cancer, 36 with colorectal cancer and 40 with chronic pancreatitis). These markers were determined in the serum by chemiluminescence immunoassay (CA 72-4) or microparticle enzyme immunoassay (CA 19-9 and CEA) methods. In serodiagnostic evaluations relating to pancreatic cancer, CA 19-9 proved superior to CA 72-4 and CEA (sensitivity: 79.5 vs. 56.5 and 62.5%; specificity: 84.1 vs. 77.9 and 77.2%; diagnostic accuracy: 85.9 vs. 75.8 and 75.7%, respectively). For gastric carcinoma, CA 72-4 appeared the most sensitive: 53.1% of all patients were identified with a specificity of 78.9% and a diagnostic accuracy of 75.4%. In the diagnosis; of colorectal cancer, CEA exhibited the highest sensitivity (63.9%) and diagnostic accuracy (76.2%). Elevated CA 19-9 levels were obtained in only 7.7% of patients with chronic pancreatitis. Tumor marker determination is useful in the diagnosis of gastrointestinal malignancies: the marker of choice in pancreatic cancer is CA 19-9, in gastric cancer it is CA 72-4 and in colorectal cancer it is CEA. CA 19-9 is effective in discriminating between pancreatic cancer and chronic pancreatitis.

AB - The diagnostic value of CA 19-9, CA 72-4 and CEA was evaluated in 291 patients (including 39 with pancreatic cancer, 32 with gastric cancer, 36 with colorectal cancer and 40 with chronic pancreatitis). These markers were determined in the serum by chemiluminescence immunoassay (CA 72-4) or microparticle enzyme immunoassay (CA 19-9 and CEA) methods. In serodiagnostic evaluations relating to pancreatic cancer, CA 19-9 proved superior to CA 72-4 and CEA (sensitivity: 79.5 vs. 56.5 and 62.5%; specificity: 84.1 vs. 77.9 and 77.2%; diagnostic accuracy: 85.9 vs. 75.8 and 75.7%, respectively). For gastric carcinoma, CA 72-4 appeared the most sensitive: 53.1% of all patients were identified with a specificity of 78.9% and a diagnostic accuracy of 75.4%. In the diagnosis; of colorectal cancer, CEA exhibited the highest sensitivity (63.9%) and diagnostic accuracy (76.2%). Elevated CA 19-9 levels were obtained in only 7.7% of patients with chronic pancreatitis. Tumor marker determination is useful in the diagnosis of gastrointestinal malignancies: the marker of choice in pancreatic cancer is CA 19-9, in gastric cancer it is CA 72-4 and in colorectal cancer it is CEA. CA 19-9 is effective in discriminating between pancreatic cancer and chronic pancreatitis.

UR - http://www.scopus.com/inward/record.url?scp=0031584555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031584555&partnerID=8YFLogxK

M3 - Article

C2 - 9432648

AN - SCOPUS:0031584555

VL - 138

SP - 2981

EP - 2985

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -